Cancer Research UK Manchester Institute shared a post on LinkedIn:
“Today we welcomed Professor Samra Turajlić as our new Institute Director!
Professor Turajlić joins us Director of the Cancer Research UK Manchester Institute, as Consultant Medical Oncologist at The Christie NHS Foundation Trust and as Group Leader of the Cancer Dynamics research group.
Professor Turajlić’s work spans basic, translational and cancer research, and she has led numerous pioneering studies that have significantly advanced our understanding of cancer biology and treatment.
You can read more about her appointment on our website, including messages from Michelle Mitchell OBE Chief Executive of Cancer Research UK (CRUK) and Professor Duncan Ivison President and Vice-Chancellor of The University of Manchester.
Prof Turajlic is the Chief Investigator of translational studies into melanoma and kidney cancer (TRACERx), and her research goal is to develop an evolutionary understanding of cancer for patient benefit. She is a member of the NCRI Bladder and Renal Cancer Clinical Studies Group, ESMO – European Society for Medical Oncology Faculty member for genitourinary cancers; and Scientific Committee member for ESMO, Molecular Analysis for Personalised Therapy, Kidney Cancer Association, and EORTC-NCI-AACR Symposia.
She is a Trustee of the Kidney Cancer Support Network and Melanoma Focus, and a Senior Editor at Macmillan Cancer Support. Prof Turajlić receives research funding from Cancer Research UK (CRUK), Rosetrees Trust, the The Royal Marsden Cancer Charity, and the RMH/ICR Biomedical Research Centre, among others.”
More posts featuring CRUK on OncoDaily.